Clinical trials: sponsored by H. Lundbeck A/S
Schizophrenia
Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
The purpose of this study is to investigate the pharmacokinetic (PK) properties of various modified release tablet formulations of Lu AF11167 (Part A) and to investigate the pharmacokinetic (PK) properties of a modified release…
- Trial name
- NCT02260830
- Testing
- Lu AF11167
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)
The purpose of the study is to test the safety and effectiveness of the Investigational Drug on insomnia.
- Trial name
- NCT00094627
- Testing
- gaboxadol
- Volunteers
- 465 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.
- Trial name
- NCT00094666
- Testing
- MK0928, gaboxadol / Duration of Treatment - 6 weeks
- Volunteers
- 465 people
- Sponsor
- H. Lundbeck A/S
Insomnia
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.
- Trial name
- NCT00095069
- Testing
- MK0928, gaboxadol / Duration of Treatment - 1 year
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Insomnia
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)
A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).
- Trial name
- NCT00102154
- Testing
- MK0928, gaboxadol / Duration of Treatment: 10 months
- Volunteers
- healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Insomnia
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)
A study to evaluate the safety and effectiveness of Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia for insomnia (a sleep disorder).
- Trial name
- NCT00102167
- Testing
- gaboxadol
- Volunteers
- 663 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Insomnia
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)
The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).
- Trial name
- NCT00103818
- Testing
- gaboxadol
- Volunteers
- 900 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266344
- Testing
- MK0928, gaboxadol / Duration of Treatment 3 Weeks
- Volunteers
- 520 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266357
- Testing
- MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
- Volunteers
- 50 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
The purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer.
- Trial name
- NCT00420810
- Testing
- MK0928 / Duration of Treatment : 8 Weeks
- Volunteers
- 138 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Healthy Women
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women
The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following single oral doses of three modified-release (MR)…
- Trial name
- NCT02112903
- Testing
- Encapsulated vortioxetine IR tablet, 20 mg, Vortioxetine MR capsule 20 mg (pH 5.5), Vortioxetine MR capsule 20 mg (pH 6.0)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge
To contribute to the understanding of the underlying neurobiological mechanism behind the interaction of alcohol and nalmefene
- Trial name
- NCT01969617
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
- Trial name
- NCT01571453
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine extended release
- Volunteers
- 437 people
- Sponsor
- H. Lundbeck A/S
Healthy Men
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700
- Trial name
- NCT02093169
- Testing
- Part A: Lu AF35700, Part B: Lu AF35700
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy Men and Women
Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)
To establish bioequivalence of flupentixol/melitracen between a new film-coated tablet formulation of 0.5 mg flupentixol/10 mg melitracen and the marketed coated tablet formulation of 0.5 mg flupentixol/10 mg melitracen…
- Trial name
- NCT02179931
- Testing
- Flupentixol/melitracen film-coated tablet, Flupentixol/melitracen coated tablet (Deanxit®)
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Healthy Volunteers
Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects
To examine the effect of the strong CYP3A4/5 inhibitor itraconazole (200 mg QD) on the multipledose exposure of Lu AE58054 (30 mg QD) in healthy subjects (CYP2D6 extensive metabolisers).
- Trial name
- NCT02122692
- Testing
- Lu AE58054 30 mg, Lu AE58054 30 mg + itraconazole 200 mg, Itraconazole
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Cognition
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
- Trial name
- NCT00654706
- Testing
- Sertindole, Quetiapine
- Where
- 26 sites in United States
- Volunteers
- 264 people
- Sponsor
- H. Lundbeck A/S